Fieldpoint Private Securities, LLC Viking Therapeutics, Inc. Transaction History

Fieldpoint Private Securities, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 24, 2022	SELL	$4.6 - $6.72 $11,159 - $16,302	-2,426 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$5.19 - $6.73 $160 - $208	-31 Reduced 1.26%	2,426 $14,000
Q1 2021 Apr 23, 2021	SELL	$5.74 - $9.67 $4,184 - $7,049	-729 Reduced 22.88%	2,457 $16,000
Q4 2020 Jan 28, 2021	BUY	$5.3 - $6.71 $16,885 - $21,378	3,186 New	3,186 $18,000
Q1 2020 May 11, 2020	SELL	$3.45 - $7.95 $33,423 - $77,019	-9,688 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$6.38 - $8.73 $38,286 - $52,388	6,001 Added 162.76%	9,688 $78,000
Q3 2019 Nov 07, 2019	SELL	$6.55 - $8.6 $1,978 - $2,597	-302 Reduced 7.57%	3,687 $25,000
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $30,595 - $42,403	3,989 New	3,989 $33,000

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.24B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Fieldpoint Private Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Fieldpoint Private Securities, LLC with notifications on news.